BioCentury | Sep 15, 2014
Company News

Abzena, UCL deal

...Abzena's Antitope Ltd. subsidiary and University College London partnered to humanize an anti- leucine-rich alpha-2-glycoprotein 1 (LRG1) antibody as...
...of Ophthalmology. UCL's UCL Business plc technology transfer company, which holds the patents to UCL's LRG1...
...antibodies using its Composite Human Antibody technology that are designed to bind to and inhibit LRG1...
Items per page:
1 - 1 of 1